Exelixis, Inc. (EXEL) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $26.22, down from yesterday’s close by -1.91%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
Does this stock stack up well when compared to its peers in the industry space? Let’s take a look. Exelixis, Inc. (EXEL) currently trades with a market capitalization of $7.48 Billion. That value represents a market adjusting for revenues that have been growing by 145.22 % on a quarterly year/year basis as of the company’s last quarterly report.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For EXEL, the company currently has $149.36 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $191.94 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.12 on a per share basis this quarter. Perhaps, that suggests something about why 79.74% of the outstanding share supply is held by institutional investors.
Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, Exelixis, Inc. recorded a 52-week high of $32.50. It is now trading 6.28% off that level. The stock is trading $26.03 its 50-day moving average by -0.19%. The stock carved out a 52-week low down at $14.22.
In recent action, Exelixis, Inc. (EXEL) has made a move of -1.39% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.32, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 6.33% with $278.43 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EXEL.